Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer R, Campbell R, Claggett B, Desai A, Docherty K, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Simpson J, Vaduganathan M, Jhund P, Solomon S, McMurray J. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology 2024, 9: 457-465. PMID: 38536153, PMCID: PMC10974691, DOI: 10.1001/jamacardio.2024.0284.Peer-Reviewed Original ResearchConceptsNT-proBNP levelsHF hospitalizationHeart failureCardiovascular deathNT-proBNPPARAGON-HFClinical outcomesN-terminal pro-brain natriuretic peptideAngiotensin receptor-neprilysin inhibitionComposite of HF hospitalizationSodium-glucose cotransporter 2 inhibitorsHigh-sensitivity cardiac troponin TMeta-Analysis Global GroupPro-brain natriuretic peptidePARAGON-HF trialBiomarker-driven approachesRisk of cardiovascular deathHigh-risk patientsInformed care decisionsCardiac troponin TPredictive of all-causePredictive of morbidityTransient ischemic attack/strokeChronic obstructive pulmonary diseaseObstructive pulmonary diseaseDapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER
Peikert A, Vaduganathan M, Claggett B, Kulac I, Foà A, Desai A, Jhund P, Carberry J, Lam C, Kosiborod M, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Køber L, Ponikowski P, Sabatine M, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 912-924. PMID: 38487939, DOI: 10.1002/ejhf.3184.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionHeart failureHistory of MIMyocardial infarctionPrimary outcomeDAPA-HFWorsening HFSpectrum of left ventricular ejection fractionLeft ventricular ejection fraction spectrumCardiovascular deathSodium-glucose cotransporter 2 inhibitorsRisk of disease progressionComposite of cardiovascular deathRisk of adverse cardiovascular outcomesIncreased risk of adverse cardiovascular outcomesRisk of cardiovascular deathVentricular ejection fractionHistory of myocardial infarctionSerious adverse eventsAdverse cardiovascular outcomesSymptomatic HFEjection fractionAdverse eventsCovariate-adjusted modelsPooled analysis